维普期刊资源整合服务平台（V6.5）

148篇 您的检索式：作者名="Carter SM"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
2	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang LY	2004	Cancer Res2004，64，：	1
3	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
4	BAY 43-9006 ex- hibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kina- ses involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
5	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang LY		0，，19：	1
6	BAY 43-9006 exhibits broad Spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
7	BAY 43-9006 exhibits broad spectnun oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
8	Second-trimester molecular prenatal diagnosis of sporadic Apert syndrome following suspicious ultrasound findings 显示文摘	Ferreira JC Carter SM Bernstein PS	1999	Ultrasound Obstet Gynecol1999，14，6：	1
9	BAY 43-9006 exhibits broad spectrum oral anfitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
10	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
11	BAY 43 90(/6 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK path-way and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，：	1
12	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
13	BAY 4329006 ex- hibits broad spectrum oral antitumor activity and targets the RAF /MEK/ERK pathway and receptor tyrosine kinases involved in tu- mor progression and angiogenesis 显示文摘	WILHELM SM CARTER C TANG L	2004	Cancer Res2004，64，：	1
14	BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
15	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets theRAF/MEK/ERKpathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
16	Exhibits broad spec- trum oral antltumor activity and targets the faf / reek / erk pathway and receptor tyrosine ldnases involved in tumor pro- gression and anglogencsis显示文摘	Wilhelm SM Carter C Tanq I	2004	Cancer Res2004，64，9：	1
17	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
18	BAY 43- 9006 exhibits broad spectrum oral anti - tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
19	Caspase-independent cell death in AML:caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or progno- sis显示文摘	Carter BZ Komblau SM Tsao T	2003	Blood2003，102，12：	1
20	BAY 43 - 9006 exbibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示